Latest FIGO staging for cervical carcinoma
Prof Denis Querleu - Claudius Regaud Cancer Center and University of Toulouse, F...
Latest FIGO staging for cervical carcinoma ( Prof Denis Querleu - Claudius Regaud Cancer Center and University of Toulouse, France )
27 Jan 2020
PARP inhibitors and immunotherapy in ovarian cancer: From research to practice
PARP inhibitors and immunotherapy in ovarian cancer: From research to practice (  )
27 Jan 2020
The age of genomic profiling
Prof Cengiz Yakicier - Acıbadem University, Istanbul, Turkey
The age of genomic profiling ( Prof Cengiz Yakicier - Acıbadem University, Istanbul, Turkey )
27 Jan 2020
Identifying BRCA mutations for breast and ovarian cancer
Prof Alena Savanevich - Grodno State Medical University, Grodno, Belarus
Identifying BRCA mutations for breast and ovarian cancer ( Prof Alena Savanevich - Grodno State Medical University, Grodno, Belarus )
27 Jan 2020
Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause i...
Prof Deborah Fenlon - Swansea University, Swansea, UK
Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause in breast cancer survivors ( Prof Deborah Fenlon - Swansea University, Swansea, UK )
12 Dec 2019
What should be the HPV vaccine strategy for India?
Dr Rengaswamy Sankaranarayanan - WHO-IARC, Lyon, France
What should be the HPV vaccine strategy for India? ( Dr Rengaswamy Sankaranarayanan - WHO-IARC, Lyon, France )
7 Nov 2019
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer
Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer ( Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain )
7 Oct 2019
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma
Dr Jonathan Ledermann - University College Hospital, London, UK
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma ( Dr Jonathan Ledermann - University College Hospital, London, UK )
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
Ovarian highlights from ESMO 2019
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
Ovarian highlights from ESMO 2019 ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fall...
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer ...
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )
28 Sep 2019